Healthy Volunteers Clinical Trial
— FLORIDEOfficial title:
Effects of Consumption of Orange Juice on Vascular Protection and Immune Function: Clinical Study on the Specific Contribution of Citrus Flavanones
| Verified date | September 2009 |
| Source | University Hospital, Clermont-Ferrand |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | France: Ministry of Health |
| Study type | Interventional |
Epidemiological studies have firmly established the health effects of high intakes of fruits
and vegetables and in particular in regards to the prevention of cardiovascular diseases.
Citrus fruits are the most widely consumed throughout the world, mainly as juice. Citrus
fruits are rich in vitamin C but also in various plant micronutrients which are the most
abundant polyphenols. Several in vitro studies and animal models suggest that the
polyphenols of citrus are involved in the protective effects of citrus vis-à-vis the
cardiovascular diseases. However, profits in health associated with taking these polyphenols
are unknown and so far no clinical studies have been conducted to determine the contribution
of polyphenols of citrus in this protection.
The main objectives of this project are (1) to characterize the effects of single dose and
made repeated consumption of orange juice on vascular protection and the immune response and
(2) to assess the specific role of polyphenols present in citrus fruits in this protection.
To do this the investigators will conduct a clinical study, randomized and crossover, among
healthy men 50 to 65 years that are slightly overweight. These volunteers, who continue to
follow their usual diet, should consume daily for 4 weeks (1) orange juice or (2) an
isocaloric control beverage or (3) the same drink spiked with a dose of polyphenols similar
to that given by orange juice.
| Status | Completed |
| Enrollment | 24 |
| Est. completion date | April 2008 |
| Est. primary completion date | February 2008 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Male |
| Age group | 50 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - Males - Age: 50 to 65 inclusive - Body mass index of 25 to 30 kg / m² (inclusive Exclusion Criteria: - Hypertriglyceridemia or known hypercholesterolemia, treated or not - Serology HIV and / or HCV positive |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Clermont-Ferrand | Institut National de la Recherche Agronomique |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Determine the effects of repeated consumption of orange juice or purified flavanones in immune function | after consumption of orange juice | Yes | |
| Secondary | Measuring the impact of consumption of orange juice or purified flavanones on acid-base balance | after consumption of orange juice | Yes | |
| Secondary | Evaluate the effects of chronic consumption of orange juice or purified flavanones on gene expression by a global transcriptomic approach in mononuclear cells from peripheral blood | after consumption of orange juice | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
| Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
| Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
| Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
| Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
| Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
| Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
| Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
| Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
| Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
| Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
| Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
| Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
| Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |